Better Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.58
- Today's High:
- $0.6089
- Open Price:
- $0.599
- 52W Low:
- $0.589
- 52W High:
- $2.8
- Prev. Close:
- $0.586
- Volume:
- 56717
Company Statistics
- Market Cap.:
- $23.16 million
- Book Value:
- -0.412
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-674000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -89.08%
- Return on Equity TTM:
- -448.56%
Company Profile
Better Therapeutics Inc had its IPO on 2021-10-28 under the ticker symbol BTTX.
The company operates in the Healthcare sector and Biotechnology industry. Better Therapeutics Inc has a staff strength of 54 employees.
Stock update
Shares of Better Therapeutics Inc opened at $0.6 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.58 - $0.61, and closed at $0.58.
This is a -0.65% slip from the previous day's closing price.
A total volume of 56,717 shares were traded at the close of the day’s session.
In the last one week, shares of Better Therapeutics Inc have slipped by -4.87%.
Better Therapeutics Inc's Key Ratios
Better Therapeutics Inc has a market cap of $23.16 million, indicating a price to book ratio of 4.5838 and a price to sales ratio of 49559.4078.
In the last 12-months Better Therapeutics Inc’s revenue was $0 with a gross profit of $-674000 and an EBITDA of $-37697000. The EBITDA ratio measures Better Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Better Therapeutics Inc’s operating margin was 0% while its return on assets stood at -89.08% with a return of equity of -448.56%.
In Q1, Better Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Better Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Better Therapeutics Inc’s profitability.
Better Therapeutics Inc stock is trading at a EV to sales ratio of 74299.06 and a EV to EBITDA ratio of -0.6259. Its price to sales ratio in the trailing 12-months stood at 49559.4078.
Better Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $12.81 million
- Total Liabilities
- $13.64 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $521000
- Dividend Payout Ratio
- 0%
Better Therapeutics Inc ended 2024 with $12.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.81 million while shareholder equity stood at $-9833000.00.
Better Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $13.64 million in other current liabilities, 2000.00 in common stock, $-120860000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.07 million and cash and short-term investments were $6.07 million. The company’s total short-term debt was $5,539,000 while long-term debt stood at $9.00 million.
Better Therapeutics Inc’s total current assets stands at $8.44 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.51 million and inventory worth $0.
In 2024, Better Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $521000.
Comparatively, Better Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.58
- 52-Week High
- $2.8
- 52-Week Low
- $0.589
- Analyst Target Price
- $10
Better Therapeutics Inc stock is currently trading at $0.58 per share. It touched a 52-week high of $2.8 and a 52-week low of $2.8. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $0.74 and 200-day moving average was $1.03 The short ratio stood at 0.8 indicating a short percent outstanding of 0%.
Around 5605% of the company’s stock are held by insiders while 494.6% are held by institutions.
Frequently Asked Questions About Better Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.